Abstracts

COVID-19 DISPARITIES: HOW CAN THEY HELP MOVE THE NEEDLE FORWARD?

This interactive session will summarize critical data on the SARS-CoV-2 pandemic among several populations that experience disproportionate burdens of morbidity and mortality due to COVID-19. Speakers will also give recommendations or key interventions that could substantially decrease these disparities and participate in an interactive panel discussion with audience participation.

PrEP ADHERENCE INTERVENTIONS FOR ADOLESCENTS AND YOUNG ADULTS

Oral pre-exposure prophylaxis (PrEP) is a remarkably effective means of HIV prevention when taken consistently. Young African women and young men who have sex with men (MSM) in the US have demonstrated lower levels of PrEP adherence than older adults across multiple open label trials and demonstration projects. Given the biological, behavioral, and social developmental…

IMPROVING HOW WE MARKET PrEP TO YOUTH

The benefits of pre-exposure prophylaxis (PrEP) for HIV prevention are well-established, however efficacy in high-incidence locations will depend on whether young people can effectively access, use, and adhere to PrEP. Demand creation in acceptable spaces and with positive messaging not just about the benefits of PrEP but also about how PrEP can conveniently fit into…

HEPATITIS C ELIMINATION: WHAT’S TAKING SO LONG?

This talk will review current the status of the hepatitis C virus (HCV) epidemic in the US and globally, focusing on progress and impediments to meeting elimination goals. Dr Luetkemeyer will review models of successful widespread treatment and micro-elimination and strategies to address remaining barriers to elimination, including lessons learned from COVID-19 and approaches to…

MECHANISMS AND TREATMENTS OF STEATOSIS IN HIV

Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum of disease, progressing from simple steatosis, through mixed steatosis and lobular inflammation, to nonalcoholic steatohepatitis (NASH), and ultimately advancing to more advanced fibrosis, cirrhosis, and end-stage liver disease. NAFLD is a manifestation of metabolic disease, associated with obesity, visceral adiposity, and insulin resistance, and contributes to an…

HARNESSING IMMUNITY TO CURE HBV

Currently, there is no curative treatment for hepatitis B virus (HBV) infection. Available antivirals control replication and mitigate inflammation but -as in HIV infection- cannot attack the nuclear persistence form of the virus. Virus-specific immunity can eliminate and control HBV, but antibody, as well as T-cell responses, are barely detectable in chronic infection. Activating HBV-specific…

NEW PROSPECTS FOR THE TREATMENT OF HBV

In this presentation, Heiner Wedemeyer will address new drug developments for hepatitis B management and cure. He will describe strategies that utilize current therapies to harness the immune response, discuss novel agents in the pipeline, and review how to best utilize these novel therapies in order to achieve functional cure with defined treatment endpoints in…

LESSONS LEARNED AND CHALLENGES IN COVID-19 VACCINE TRIALS

In 2020, the development of SARS-CoV-2 vaccines proceeded at a historic pace. Facing many challenges early on – a new disease poorly understood immunity, and an uncertain trajectory of the outbreak – a U.S. government effort brought together many partners to develop and advance several SARS-CoV2 vaccines. The vaccine development model included harmonized trial designs,…

VACCINE ACCEPTANCE

Vaccine acceptance is a complex phenomenon that lies on a continuum with those who actively seek vaccination on one end and those who refuse all vaccines on the other. When we talk about vaccine hesitancy, we mean those who accept some, delay some, or refuse some vaccines. Where one lies on this continuum is the…